Literature DB >> 33956666

IL-23 reshapes kidney resident cell metabolism and promotes local kidney inflammation.

Hao Li1, Maria G Tsokos1, Rhea Bhargava1, Iannis E Adamopoulos1, Hanni Menn-Josephy2, Isaac E Stillman3, Philip Rosenstiel4, Jarrat Jordan5, George C Tsokos1.   

Abstract

Interstitial kidney inflammation is present in various nephritides in which serum interleukin 23 (IL-23) is elevated. Here we showed that murine and human renal tubular epithelial cells (TECs) expressing the IL-23 receptor (IL-23R) responded to IL-23 by inducing intracellular calcium flux, enhancing glycolysis, and upregulating calcium/calmodulin kinase IV (CaMK4), which resulted in suppression of the expression of the arginine-degrading enzyme arginase 1 (ARG1), thus increasing in situ levels of free L-arginine. Limited availability of arginine suppressed the ability of infiltrating T cells to proliferate and produce inflammatory cytokines. TECs from humans and mice with nephritis expressed increased levels of IL-23R and CaMK4 but reduced levels of ARG1. TEC-specific deletion of Il23r or Camk4 suppressed inflammation, whereas deletion of Arg1 exacerbated inflammation in different murine disease models. Finally, TEC-specific delivery of a CaMK4 inhibitor specifically curbed renal inflammation in lupus-prone mice without affecting systemic inflammation. Our data offer the first evidence to our knowledge of the immunosuppressive capacity of TECs through a mechanism that involves competitive uptake of arginine and signify the importance of modulation of an inflammatory cytokine in the function of nonlymphoid cells, which leads to the establishment of an inflammatory microenvironment. New approaches to treat kidney inflammation should consider restoring the immunosuppressive capacity of TECs.

Entities:  

Keywords:  Autoimmune diseases; Autoimmunity

Year:  2021        PMID: 33956666      PMCID: PMC8203450          DOI: 10.1172/JCI142428

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  69 in total

Review 1.  A guide to immunometabolism for immunologists.

Authors:  Luke A J O'Neill; Rigel J Kishton; Jeff Rathmell
Journal:  Nat Rev Immunol       Date:  2016-07-11       Impact factor: 53.106

2.  In situ B cell-mediated immune responses and tubulointerstitial inflammation in human lupus nephritis.

Authors:  Anthony Chang; Scott G Henderson; Daniel Brandt; Ni Liu; Riteesha Guttikonda; Christine Hsieh; Natasha Kaverina; Tammy O Utset; Shane M Meehan; Richard J Quigg; Eric Meffre; Marcus R Clark
Journal:  J Immunol       Date:  2010-12-27       Impact factor: 5.422

3.  Experimental glomerulonephritis.

Authors:  D J Salant; A V Cybulsky
Journal:  Methods Enzymol       Date:  1988       Impact factor: 1.600

4.  Cutting edge: IL-23 receptor deficiency prevents the development of lupus nephritis in C57BL/6-lpr/lpr mice.

Authors:  Vasileios C Kyttaris; Zheng Zhang; Vijay K Kuchroo; Mohamed Oukka; George C Tsokos
Journal:  J Immunol       Date:  2010-03-22       Impact factor: 5.422

5.  Calcium restores a normal proliferation phenotype in human polycystic kidney disease epithelial cells.

Authors:  Tamio Yamaguchi; Scott J Hempson; Gail A Reif; Anne-Marie Hedge; Darren P Wallace
Journal:  J Am Soc Nephrol       Date:  2005-11-30       Impact factor: 10.121

6.  Renal tubular epithelial cells modulate T-cell responses via ICOS-L and B7-H1.

Authors:  Simone de Haij; Andrea M Woltman; Leendert A Trouw; Astrid C Bakker; Sylvia W Kamerling; Sandra W van der Kooij; Lieping Chen; Richard A Kroczek; Mohamed R Daha; Cees van Kooten
Journal:  Kidney Int       Date:  2005-11       Impact factor: 10.612

7.  Normalization of CD4+ T cell metabolism reverses lupus.

Authors:  Yiming Yin; Seung-Chul Choi; Zhiwei Xu; Daniel J Perry; Howard Seay; Byron P Croker; Eric S Sobel; Todd M Brusko; Laurence Morel
Journal:  Sci Transl Med       Date:  2015-02-11       Impact factor: 17.956

8.  Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys.

Authors:  José C Crispín; Mohamed Oukka; George Bayliss; Robert A Cohen; Christine A Van Beek; Isaac E Stillman; Vasileios C Kyttaris; Yuang-Taung Juang; George C Tsokos
Journal:  J Immunol       Date:  2008-12-15       Impact factor: 5.422

Review 9.  Regulation of innate immune cell function by mTOR.

Authors:  Thomas Weichhart; Markus Hengstschläger; Monika Linke
Journal:  Nat Rev Immunol       Date:  2015-10       Impact factor: 53.106

10.  Spontaneous murine lupus-like syndromes. Clinical and immunopathological manifestations in several strains.

Authors:  B S Andrews; R A Eisenberg; A N Theofilopoulos; S Izui; C B Wilson; P J McConahey; E D Murphy; J B Roths; F J Dixon
Journal:  J Exp Med       Date:  1978-11-01       Impact factor: 14.307

View more
  5 in total

Review 1.  Signaling pathways of chronic kidney diseases, implications for therapeutics.

Authors:  Qian Yuan; Ben Tang; Chun Zhang
Journal:  Signal Transduct Target Ther       Date:  2022-06-09

2.  Oral Cholecalciferol Supplementation in Sahara Black People with Chronic Kidney Disease Modulates Cytokine Storm, Oxidative Stress Damage and Athero-Thromboembolic Risk.

Authors:  Houda Zoubiri; Amina Tahar; Samir AitAbderrhmane; Messaoud Saidani; Elhadj-Ahmed Koceir
Journal:  Nutrients       Date:  2022-05-29       Impact factor: 6.706

3.  Cosmc deficiency causes spontaneous autoimmunity by breaking B cell tolerance.

Authors:  Junwei Zeng; Rajindra P Aryal; Kathrin Stavenhagen; Chi Luo; Renyan Liu; Xiaohui Wang; Jiaxuan Chen; Hao Li; Yasuyuki Matsumoto; Yingchun Wang; Jianmei Wang; Tongzhong Ju; Richard D Cummings
Journal:  Sci Adv       Date:  2021-10-06       Impact factor: 14.136

4.  Lymphocytes in the neighborhood: good or bad for the kidney?

Authors:  Hao Li; Maria G Tsokos; George C Tsokos
Journal:  J Clin Invest       Date:  2022-07-01       Impact factor: 19.456

5.  Tissue-specific therapy in immune-mediated kidney diseases: new ARGuments for targeting the IL-23/IL-17 axis.

Authors:  Christian F Krebs; Jan-Eric Turner; Jan-Hendrik Riedel; Ulf Panzer
Journal:  J Clin Invest       Date:  2021-06-15       Impact factor: 19.456

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.